In summary, the highly selective HDAC6 inhibitor NN-429 exhibited strong selective cytotoxicity as a single agent, and synergy with clinical agents cytarabine, doxorubicin, etoposide, and SNS-32 in cellular models of γδ T-NHL and NKTCL. This evidence concerns the gene HDAC6 and non-Hodgkin lymphoma.